Zou C, Huang R, Lin T, Wang Y, Tu J, Zhang L
Front Oncol. 2024; 14:1382276.
PMID: 38841159
PMC: 11150704.
DOI: 10.3389/fonc.2024.1382276.
Bodea J, Caldwell K, Federico S
Front Oncol. 2022; 12:864790.
PMID: 35692751
PMC: 9174993.
DOI: 10.3389/fonc.2022.864790.
Ollauri-Ibanez C, Astigarraga I
Cancers (Basel). 2021; 13(2).
PMID: 33445470
PMC: 7827326.
DOI: 10.3390/cancers13020253.
Nazam N, Lone M, Hamid A, Qadah T, Banjar A, Alam Q
Toxics. 2020; 8(4).
PMID: 33019668
PMC: 7712428.
DOI: 10.3390/toxics8040080.
Huang F, Liao F, Ma G, Hu Y, Zhang C, Xu P
Onco Targets Ther. 2020; 13:7271-7281.
PMID: 32801755
PMC: 7394601.
DOI: 10.2147/OTT.S249477.
Locally Controlled Release of Methotrexate and Alendronate by Thermo-Sensitive Hydrogels for Synergistic Inhibition of Osteosarcoma Progression.
Shan H, Li K, Zhao D, Chi C, Tan Q, Wang X
Front Pharmacol. 2020; 11:573.
PMID: 32508628
PMC: 7248331.
DOI: 10.3389/fphar.2020.00573.
Bone morphogenetic protein 9 is a potential tumor suppressor in osteosarcoma.
Liang J, Zhang J, Chen F, Lian Z, Dong Y, Lu N
Int J Clin Exp Pathol. 2020; 10(11):11030-11036.
PMID: 31966448
PMC: 6965842.
miR-509-5p Inhibits the Proliferation and Invasion of Osteosarcoma by Targeting TRIB2.
Guo J, Wu Q, Peng X, Yu B
Biomed Res Int. 2020; 2019:2523032.
PMID: 31930114
PMC: 6942763.
DOI: 10.1155/2019/2523032.
Doxorubicin·Hydrochloride/Cisplatin-Loaded Hydrogel/Nanosized (2-Hydroxypropyl)-Beta-Cyclodextrin Local Drug-Delivery System for Osteosarcoma Treatment In Vivo.
Yoon S, Moon Y, Chun H, Yang D
Nanomaterials (Basel). 2019; 9(12).
PMID: 31766334
PMC: 6956151.
DOI: 10.3390/nano9121652.
Potential Regulatory Effects of miR-182-3p in Osteosarcoma via Targeting EBF2.
Chen G, Yu W, Li Z, Wang Q, Yang Q, Du Z
Biomed Res Int. 2019; 2019:4897905.
PMID: 30993113
PMC: 6434304.
DOI: 10.1155/2019/4897905.
Increased survival of patients aged 0-29 years with osteosarcoma: A period analysis, 1984-2013.
Wu J, Sun H, Li J, Guo Y, Zhang K, Lang C
Cancer Med. 2018; 7(8):3652-3661.
PMID: 29992762
PMC: 6089162.
DOI: 10.1002/cam4.1659.
Baicalein induces cervical cancer apoptosis through the NF-κB signaling pathway.
Yu X, Liu Y, Wang Y, Mao X, Zhang Y, Xia J
Mol Med Rep. 2018; 17(4):5088-5094.
PMID: 29393414
PMC: 5865972.
DOI: 10.3892/mmr.2018.8493.
CD99/MIC2 Constitutes a Differentiation Antigen of a Human Osteoblast Cell Line.
Hamilton G, Olszewski-Hamilton U
World J Oncol. 2017; 2(6):298-304.
PMID: 29147265
PMC: 5649714.
DOI: 10.4021/wjon415w.
The RhoE/ROCK/ARHGAP25 signaling pathway controls cell invasion by inhibition of Rac activity.
Thuault S, Comunale F, Hasna J, Fortier M, Planchon D, Elarouci N
Mol Biol Cell. 2016; 27(17):2653-61.
PMID: 27413008
PMC: 5007086.
DOI: 10.1091/mbc.E16-01-0041.
Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma.
Shaikh A, Li F, Li M, He B, He X, Chen G
Int J Mol Sci. 2016; 17(4):506.
PMID: 27058531
PMC: 4848962.
DOI: 10.3390/ijms17040506.
Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem-like cell population.
Ciccarelli C, Vulcano F, Milazzo L, Gravina G, Marampon F, Macioce G
Mol Cancer. 2016; 15:16.
PMID: 26897742
PMC: 4761200.
DOI: 10.1186/s12943-016-0501-y.
Uncovering metabolism in rhabdomyosarcoma.
Monti E, Fanzani A
Cell Cycle. 2015; 15(2):184-95.
PMID: 26209235
PMC: 4825834.
DOI: 10.1080/15384101.2015.1071746.
ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib.
Liu J, Wu J, Zhou L, Pan C, Zhou Y, Du W
Oncotarget. 2015; 6(25):21341-52.
PMID: 26050198
PMC: 4673269.
DOI: 10.18632/oncotarget.4179.
The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma.
Fleuren E, Hillebrandt-Roeffen M, Flucke U, Loo D, Boerman O, van der Graaf W
Oncotarget. 2014; 5(24):12753-68.
PMID: 25528764
PMC: 4350331.
DOI: 10.18632/oncotarget.2648.
Protein kinase Cδ promotes proliferation and induces malignant transformation in skeletal muscle.
Czifra G, Szollosi A, Nagy Z, Boros M, Juhasz I, Kiss A
J Cell Mol Med. 2014; 19(2):396-407.
PMID: 25283340
PMC: 4407591.
DOI: 10.1111/jcmm.12452.